Incyte Corporation (BIT:1INCY)

Market Cap	10.59B
Revenue (ttm)	4.08B
Net Income (ttm)	19.68M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	538.27
Forward PE	10.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	131
Open	55.20
Previous Close	55.20
Day's Range	55.20 - 55.20
52-Week Range	47.33 - 79.44
Beta	n/a
RSI	55.45
Earnings Date	Apr 29, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD